Anna Daily, who invented a breast cancer screening that analyzes teardrops, has been promoted to vice president of product development and innovation at Namida Lab Inc. of Fayetteville.
Daily, who received her Ph.D. in cellular and molecular biology from the University of Arkansas in 2007, was previously the company’s director of clinical and regulatory affairs. As vice president, Daily will establish clinical, industrial and academic partnerships in Arkansas and across the country, and oversee all product development and innovation activities.
Founded in 2019, Namida develops medical screening and diagnostic tools. Daily, a specialist in protein characterization, biomarker discovery and validation, developed the tear-based test, known as Melody, for Namida. She presented it as a national finalist in the InnovateHer business competition in Washington in 2015.
In 2016, Daily collaborated with international ad agency DDB to develop a national breast cancer awareness campaign in New Zealand featuring the new screening.
Daily now brings her expertise in protein characterization, biomarker discovery, validation and assay development to Namida Lab.
Omid Moghadam, Namida’s founder and CEO, praised Daily’s “untiring tenacity” in leading the company’s research, and her “vision for women of all backgrounds to have access to breast health screening that is affordable and accessible for all.”